Biodegradable carbamate lipids with increased stability
Patent Information
- Application Number
- HK62026124900
- Authority / Receiving Office
- HK · HK
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-06-13
- Filing Date
- 2026-06-16
- Publication Date
- 2026-09-11
Smart Images

Figure 00000000_0000_ABST
Abstract
Description
Abstract This invention provides lipids and lipid nanoparticle formulations comprising these lipids (alone or in combination with other lipids). These lipid nanoparticles can be co-formulated with nucleic acids to facilitate their intracellular delivery in in vitro and in vivo therapeutic applications. The lipids of this invention are characterized by significant hydrolytic and alcoholysis stability while maintaining their biological activity.
Claims
CLAIMSWhat is claimed is:
1. A lipid represented by the structure of Formula (V) or a salt thereof:each one of n and m is individually selected from the group consisting of: 1, 2, 3, 4 and 5;R1is selected from the group consisting of: C3-9alkylene-CO2-C8-18alkyl, C3-9alkylene-CO2-C8-18alkenyl, C3-9alkenylene-CCF-C8-18alkyl, C3-9alkenylene- CO2-C8-18alkenyl, C3-9alkylene-O2C-C8-18alkyl, C3-9alkylene-O2C-C8-18alkenyl, C3-9alkenylene-CFC-C8-18alkyl and C3-9alkenylene-CFC-C8-18alkenyl;R2is selected from the group consisting of: C10-20alkyl, C10-20alkenyl, C10-20alkynyl, C3-9alkylene-CO2-C8-18alkyl, C3-9alkylene-CO2-C8-18alkenyl, C3-9alkenylene-CO2-C8-18alkyl, C3-9alkenylene-CCF-C8-18alkenyl, C3-9alkylene- O2C-C8-18alkyl, C3-9alkylene-O2C-C8-18alkenyl, C3-9alkenylene- O2C-C8-18alkyl and C3-9alkenylene-CFC-C8-18alkenyl; and each one of R3and R4is individually, a C1-4 alkyl or wherein R3and R4together with the nitrogen atom to which they are bound form a 5-6 membered ring.
2. The lipid according to claim 1, wherein n is 2, 3 or 4.
3. lipid according to claim 2, wherein n is 2.
4. The lipid according to any one of claims 1 to 3, wherein m is 2, 3 or 4.
5. The lipid according to claim 5, wherein m is 2.
6. The lipid according to any one of claims 1 to 5, wherein each one of n and m is 2, and the lipid is represented by the structure of Formula (III) or a salt thereof:
7. The lipid according to any one of claims 1 to 6, wherein each one of R3and R4is individually, a C1-4alkyl.
8. The lipid according to any one of claims 1 to 7, wherein R3is a C1-2alkyl.
9. The lipid according to claim 8, wherein R3is CH3.
10. The lipid according to any one of claims 1 to 9, wherein R4is a C1-2alkyl.
11. The lipid according to claim 10, wherein R4is CH3.
12. The lipid according to claim 1, wherein each one of n and m is 2, each one of R3andR4is individually CH3, and the lipid is represented by the structure of Formula (IV) or a salt thereof:
13. The lipid according to any one of claims 1 to 12, wherein R1is selected from the group consisting of: C3-9alkylene-CO2-C8-18alkyl, C3-9alkylene-CO2-C8-18alkenyl, C3-9alkenylene-CO2-C8-18alkyl, C3-9alkylene-O2C-C8-18alkyl, C3-9alkylene-O2C-C8-18alkenyl, C3-9alkenylene-O2C-C8-18alkyl.
14. The lipid according to claim 13, wherein R1is selected from the group consisting of: C3-9alkylene-CO2-C8-18alkyl and C3-9alkylene-O2C-C8-18alkyl.
15. The lipid according to claim 13, wherein R1is selected from the group consisting of: C6-9alkylene-CO2-C14-18alkyl, C6-9alkylene-O2C-C14-18alkyl.
16. The lipid according to claim 13, wherein R1is C6-9alkylene-CO2-C14-18alkyl.
17. The lipid according to any one of claims 1 to 16, wherein R2is selected from the group consisting of: C10-20alkenyl, C3-9alkylene-CO2-C8-18alkyl and C3-9alkylene-CTC-C8-18alkyl.
18. The lipid according to claim 17, wherein R2is selected from the group consisting of: C16-20 alkenyl, C6-9alkylene-CO2-C14-18alkyl and C6-9alkylene-O2C-C14-18alkyl.
19. The lipid according to any one of claims 1 to 19, wherein each one of R1and R2is individually selected from the group consisting of: C3-9alkylene-CO2-C8-18alkyl, C3-9alkylene-CO2-C8-18alkenyl, C3-9alkenylene-CCT-C8-18alkyl, C3-9alkylene- O2C-C8-18alkyl, C3-9alkylene-O2C-C8-18alkenyl, C3-9alkenylene-O2C-C8-18alkyl.
20. The lipid according to claim 20, wherein each one of R1and R2is individually selected from the group consisting of: C3-9alkylene-CO2-C8-18alkyl and C3-9alkylene-CTC-C8-18alkyl.
21. The lipid according to any claim 21, wherein each one of R1and R2is C6-9alkylene- CO2— C14-18alkyl.
22. The lipid according to any one of claims 1 to 13 or 17 to 19, wherein each one of the alkenyl groups is unsubstituted.
23. The lipid according to any one of claims 1 to 13, 19 or 22, wherein each one of the alkenylene groups is unsubstituted.
24. The lipid according to any one of claims 1 to 23, wherein each one of the alkyl and alkylene groups is unsubstituted.
25. The lipid according to claim 1, which is selected from the group consisting of:and salts thereof.
26. The lipid according to claim 25, which is selected from the group consisting of: EA- 405C, EA-506C, EA-513C, EA-524C and salts thereof.
27. The lipid according to claim 25, which is EA-524C or a salt thereof.
28. The lipid according to claim 1 , which is hydrolytically stable, alcoholytically stable or both, for at least one week.
29. A particle comprising the lipid according to any one of claims 1 to 28 and a membrane stabilizing lipid.
30. The particle according to claim 29, wherein the membrane stabilizing lipid is selected from the group consisting of cholesterol, phospholipids, cephalins, sphingolipids and glycoglycerolipids.
31. The particle according to any one of claims 29 to 31, wherein the membrane stabilizing lipid comprises cholesterol.
32. The particle according to any one of claims 29 to 31 , further comprising one or more additional components selected from the group consisting of a PEG-lipid conjugate, a neutral lipid and a charged lipid.
33. The particle according to claim 32, wherein the additional component comprises 1,2- Distearoyl-sn-glycero-3-phosphocholine (DSPC).
34. The particle according to any one of claims 32 to 33, wherein the additional component comprises 1,2-Dimyristoyl-sn-glyceryl-methoxy polyethylene glycol (DMG-PEG).
35. The particle according to any one of claims 29 to 34, comprising the lipid, cholesterol, 1 ,2-Distearoyl-sn-glycero-3 -phosphocholine (DSPC) and 1,2-Dimyristoyl-sn-glyceryl-methoxy polyethylene glycol (DMG-PEG).
36. The particle according to any one of claims 29 to 35, further comprising a nucleic acid encapsulated within a particle comprising the lipid.
37. The particle according to claim 36, wherein the nucleic acid is selected from the group consisting of small interfering RNA (siRNA), micro RNA (miRNA), antisense oligo nucleotides, messenger RNA (mRNA), ribozymes, pDNA, CRISPR mRNA, gRNA, circular RNA and immune stimulating nucleic acids.
38. The particle according to claim 37, wherein the nucleic acid is RNA comprising an open reading frame encoding a polypeptide that comprises a SARS-CoV-2 spike protein or an immunogenic fragment or variant thereof.
39. A composition comprising a plurality of particles according to any one of claims 29 to 38 and a pharmaceutically acceptable carrier, diluent or excipient.
40. The composition according to claim 39, being a liposomal composition.
41. A method of gene silencing, the method comprising the step of contacting a cell with a composition comprising a plurality of particles according to any one of claims 29 and 37 and a pharmaceutically acceptable carrier, diluent or excipient.
42. The method according to claim 41, wherein the cell is a cancer cell.
43. A method for administering a therapeutic agent, the method comprising the step of preparing a composition comprising a lipid according to any one of claims 1 to 28, and a therapeutic agent, and administering the composition to a subject in need thereof.
44. The method according to claim 43, further comprising encapsulating the therapeutic agent within a particle comprising the lipid.
45. The method of any one of claims 43 to 44, wherein the therapeutic agent is RNA comprising an open reading frame encoding a polypeptide that comprises a SARS- CoV-2 spike protein or an immunogenic fragment or variant thereof.
46. A method of treating a leukocyte associated condition, the method comprising the step of administering to a subject in need thereof a composition comprising a plurality of particles according to any one of claims 29 and 37 and a pharmaceutically acceptable carrier, diluent or excipient.
47. The method according to claim 46, wherein the leukocyte associated condition is selected from the group consisting of cancer, infection, autoimmune diseases, neurodegenerative diseases and inflammation.
48. A lipid represented by the structure of Formula (I) or a salt thereof:wherein one of Y and Z is O and the other of Y and Z is NH; each one of n and m is individually selected from the group consisting of: 1, 2, 3, 4 and 5; each one of R1and R2is individually selected from the group consisting of: C10-20alkyl, C10 -20 alkenyl, C10-20alkynyl, C3-9alkylene-CO2-C8-18alkyl, C3-9alkylene- CO2-C8-18alkenyl, C3-9alkenylene-CO2-C8-18alkyl, C3-9alkenylene-CO2-C8-18alkenyl, C3-9alkylene-O2C-C8-18alkyl, C3-9alkylene-O2C-C8-18alkenyl, C3-9alkenylene- O2C-C8-18alkyl and C3-9alkenylene-O2C-C8-18alkenyl; and each one of R3and R4is individually, a C1-4alkyl or wherein R3and R4together with the nitrogen atom to which they are bound form a 5-6 membered ring; wherein the lipid is hydrolytically stable for at least 2 hours.
